

Mylan buys marketing rights from Israeli company

April 11, 2018 | News

Mapi Pharma has strong research capabilities in the development of long-acting depot injections.



Mylan, one of the world's leading pharmaceutical companies, and Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, have announced that the two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product.

GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis, or RRMS. Multiple sclerosis (MS) organizations have estimated that 2.3 million individuals are living with MS worldwide. In the U.S., preliminary results of an MS prevalence study by the National MS Society estimate that nearly 1 million people are living with MS. Relapsing-remitting MS accounts for approximately 85 per cent of initial MS diagnoses.

Mapi Pharma has strong research capabilities in the development of long-acting depot injections. Mylan brings to this collaboration its regulatory expertise, unique global commercial platform and significant experience in launching other Glatiramer Acetate injection products. The partnership is subject to approval by the Israeli Innovation Authority.